Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain? Moya-Alarcon C, Gonzalez-Dominguez A, Ivanova-Markova Y, Gimeno-Ballester V, et al. Gynecol Oncol 2021 Nov 26. pii: S0090-8258(21)01604.

Read + Share

Amedeo Smart

Independent Medical Education

Moya-Alarcon C, Gonzalez-Dominguez A, Ivanova-Markova Y, Gimeno-Ballester V, et al. Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain? Gynecol Oncol 2021 Nov 26. pii: S0090-8258(21)01604.
PMID: 34844775